Journal
CLINICAL NUCLEAR MEDICINE
Volume 47, Issue 12, Pages 1116-1117Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/RLU.0000000000004389
Keywords
statin; PET/CT; F-18-FDG; SAMS; myositis
Funding
- GE Healthcare
- CHR d'Orleans
Ask authors/readers for more resources
This case illustrates the possibility of increased muscular F-18-FDG uptake without myositis in patients with statin-associated muscle symptoms. Discontinuation of statin treatment for one week can reduce muscular uptake.
Statin-associated muscle symptoms are a frequent adverse effect of statin treatment and can lead to a statin-associated myopathy characterized by a significant serum creatine kinase increase. We report the case of an 80-year-old man who presented an increased muscular F-18-FDG uptake in a statin-associated muscle symptom without creatine kinase abnormality or inflammation. Statin treatment was discontinued for 6 hours, 3 days, and 7 days on consecutive follow-up examinations. The 1-week window clearly enhanced image quality. This case illustrates the possibility of diffuse muscular F-18-FDG uptake without myositis and the need for a minimal 1-week statin discontinuation to reduce muscular uptake.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available